BDX · Healthcare

BECTON DICKINSON & CO

Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: what to focus on this earnings window

News · 2026-08-07

• Guidance / OutlookImportance 51 · Surprise 60
  BD raised its fiscal 2026 adjusted diluted EPS guidance midpoint to $12.67 and expects revenue growth toward the high end of its previously stated range. Third-party reporting attributed the improved outlook to…
• Trade Policy and TariffsImportance 51 · Surprise 50
  Third-party coverage identified tariffs as a continuing pressure on BD’s adjusted gross and operating margins in fiscal 2026. The reported Q3 adjusted operating margin was 24.9%, down 130 basis points year over year,…
• Gross Margin DriversImportance 31 · Surprise 32
  Third-quarter adjusted gross margin was 54.3%, reflecting pressure from tariffs and other cost increases. Volatility in oil prices was expected to increase costs for resin and molded plastics used in medical-device…
• Operating Income and MarginsImportance 31 · Surprise 32
  Third-quarter adjusted operating margin was 24.9%, down 130 basis points from the prior-year period. Margin pressure reflected tariffs and ongoing investments despite broad-based revenue growth. The company cited…
• Licensing / Collaboration DealsImportance 31 · Surprise 42
  BD partnered with EMS to launch a semaglutide therapy in Brazil using BD’s Vystra injection pen. The initiative expands BD’s drug-delivery-device presence in Brazil and links its pen technology to the country’s GLP-1…

10-Q · 2026-08-06

• Capital Return ProgramImportance 83 · Surprise 82
  BD paid $875 million of cash dividends to common shareholders during the first nine months of fiscal 2026. BD repurchased approximately $2.250 billion of common stock during the same period, compared with $750 million…
• Acquisition / Partnership / DivestitureImportance 71 · Surprise 60
  On February 9, 2026, BD completed the spin-off of its former Biosciences and Diagnostic Solutions business and its combination with Waters Corporation in a Reverse Morris Trust transaction. The former Life Sciences…
• Liquidity and Debt PositionImportance 66 · Surprise 40
  At June 30, 2026, BD held $864 million of cash, equivalents and short-term investments, including restricted cash. Total debt declined to $16.808 billion from $19.180 billion at September 30, 2025, and debt as a…
• Headcount / RestructuringImportance 58 · Surprise 42
  BD recorded $450 million of non-cash asset impairment charges in the first nine months of fiscal 2026. The charges followed a commitment to exit operational activities and projects that no longer align with the…
• Income Tax Rate ChangesImportance 50 · Surprise 58
  The nine-month effective tax rate for continuing operations increased to 19.8% in fiscal 2026 from 16.7% in fiscal 2025. The increase reflected recognition of a deferred tax liability after BD decided to distribute…
• Segment Revenue PerformanceImportance 49 · Surprise 32
  Third-quarter revenue increased 4.5% in Medical Essentials to $1.675 billion, 4.9% in Connected Care to $1.224 billion, and 6.4% in Interventional to $1.414 billion. BioPharma Systems revenue increased 6.6%, driven by…
• Revenue Performance and MixImportance 49 · Surprise 32
  Third-quarter worldwide revenue increased 5.4%, with volume and other factors contributing 4.1 percentage points. Connected Care benefited from a strong backlog of customer orders in Medication Management Solutions,…
• Geographic Market CommentaryImportance 49 · Surprise 32
  U.S. third-quarter revenue grew 6.9%, with strong sales across Medical Essentials, Connected Care Medication Management Solutions, BioPharma Systems, and Interventional Peripheral Intervention and Urology and Critical…
• Gross Margin DriversImportance 45 · Surprise 50
  Third-quarter gross margin declined to 46.4% from 47.3% a year earlier, a 90-basis-point decrease. Operating performance reduced the quarterly margin by 0.8 percentage points, primarily because of tariffs, higher labor…
• FDA El Paso Warning LetterImportance 44 · Surprise 60
  On April 30, 2026, BD’s El Paso manufacturing facility received a Warning Letter from the FDA’s Center for Drug Evaluation and Research following an October 2025 inspection of drug-device combination products,…
• Capital ExpendituresImportance 42 · Surprise 14
  BD invested $376 million in capital expenditures during the first nine months of fiscal 2026, compared with $383 million in the prior-year period. The capital program focused on projects that improve the cost…
• Trade Policy and TariffsImportance 40 · Surprise 42
  Tariffs, sanctions and other trade barriers imposed by or against the United States adversely affected BD’s third-quarter fiscal 2026 operating expense and are expected to continue affecting fiscal 2026 and potentially…
• Regulatory Approval MilestonesImportance 40 · Surprise 42
  BD remains subject to an amended FDA consent decree governing its U.S. infusion-pump operations, with the FDA continuing to review observations from a 2024 Form 483 and the company’s corrective action plan. The decree…
• Ethylene Oxide CostsImportance 40 · Surprise 42
  BD’s ethylene oxide sterilization facilities received a two-year Presidential compliance exemption from the EPA’s revised NESHAP requirements, but BD continues implementing facility changes and new emissions-control…
• Ethylene Oxide RegulationImportance 40 · Surprise 42
  The EPA and state environmental regulators are increasing scrutiny of ethylene oxide emissions, which could require BD or its sterilization providers to install controls, limit usage, suspend operations, or incur…
• Supply Chain ConstraintsImportance 37 · Surprise 42
  BD said major disruptions in sourcing, manufacturing or distribution could affect product availability and results. The Middle East conflict had not significantly affected global supply or distribution as of the…
• Ethylene Oxide Sterilization CapacityImportance 37 · Surprise 42
  Ethylene oxide remains the most frequently used sterilant for U.S. medical devices and healthcare products and, in some cases, the only available option for critical products. New emissions and pesticide-use…
• Product Launch and TransitionImportance 34 · Surprise 42
  BD’s updated BD Alaris Infusion System received FDA 510(k) clearance in July 2023, supporting remediation and the system’s return to the U.S. market. The clearance includes updated hardware for PCU, large-volume,…
• Operating Expense TrendsImportance 31 · Surprise 32
  Selling and administrative expense increased to $1.261 billion in the third quarter from $1.163 billion, and to $3.703 billion for the first nine months from $3.435 billion. Selling and administrative expense…
• China Healthcare Cost ControlsImportance 29 · Surprise 24
  BD reported adverse effects from China market dynamics, including volume-based procurement programs (VoBP) and government efforts to contain healthcare costs and improve healthcare-practitioner compliance. These…
• Competition and Market ShareImportance 23 · Surprise 24
  BD reported share gains in the U.S. Medication Delivery Solutions Vascular Access Management portfolio, supported by higher infusion-set utilization following a prior-period fluid-supply disruption. The BD Vacutainer…
• Middle East Conflict ImpactImportance 17 · Surprise 24
  BD stated that the ongoing conflict in Iran and the Middle East had not significantly affected its global supply chain or product distribution as of the filing date. Continued disruption of transportation lanes and…

8-K · 2026-08-06

• Restructuring and ImpairmentsImportance 77 · Surprise 82
  Nine-month integration, restructuring and transaction expense increased 162.9% to $729 million from $277 million. Restructuring costs included $605 million through June 30, 2026, including $450 million of non-cash…
• Headcount / RestructuringImportance 77 · Surprise 82
  BD recorded $605 million of restructuring costs in the first nine months of fiscal 2026, compared with $185 million in the prior-year period. The charges included $450 million of non-cash asset impairment charges…
• Spin-off and CombinationImportance 71 · Surprise 60
  BD completed the February 9, 2026 spin-off of its former Biosciences and Diagnostic Solutions business and its combination with Waters Corporation. The former business, previously reported as the Life Sciences segment,…
• Revenue Guidance UpdateImportance 68 · Surprise 68
  BD expects fiscal 2026 reported revenue growth toward the high end of its low-single-digit-plus range and FX-neutral revenue growth in the low-single-digit range. The company raised the midpoint of adjusted diluted EPS…
• Guidance and OutlookImportance 68 · Surprise 68
  BD updated fiscal 2026 guidance on August 6, 2026, expecting reported revenue growth toward the high end of its low-single-digit-plus range and foreign-currency-neutral growth in the low-single digits. Adjusted diluted…
• Liquidity and Debt PositionImportance 66 · Surprise 40
  Cash and equivalents increased to $708 million at June 30, 2026 from $567 million at September 30, 2025, while cash, restricted cash and short-term investments totaled $864 million. Current debt obligations increased…
• Acquisition / Partnership / DivestitureImportance 65 · Surprise 60
  BD completed the February 9, 2026 spin-off of its former Biosciences and Diagnostic Solutions business and its combination with Waters Corporation. The transaction eliminated BD’s former Life Sciences segment and left…
• Cash Flow and Capital AllocationImportance 64 · Surprise 56
  Nine-month cash provided by continuing operating activities increased 33.3% to $2.104 billion from $1.578 billion. Free cash flow increased 44.6% to $1.728 billion from $1.195 billion, while capital expenditures…
• FX / Currency HeadwindsImportance 37 · Surprise 32
  Foreign-currency translation reduced international revenue growth relative to currency-neutral growth in the quarter ended June 30, 2026. International revenue increased 3.2% as reported to $1.902 billion but only 0.6%…
• Market Demand TrendsImportance 36 · Surprise 40
  Third-quarter revenue increased 5.4% year over year to $4,983 million, or 4.4% on a foreign-currency-neutral basis. Medical Essentials revenue rose 4.5% to $1,675 million, Connected Care increased 4.9% to $1,224…
• Geographic Market CommentaryImportance 36 · Surprise 40
  United States revenue increased 6.9% year over year to $3,081 million on both a reported and foreign-currency-neutral basis. International revenue rose 3.2% to $1,902 million as reported, but increased only 0.6% on a…
• Litigation and Legal RiskImportance 36 · Surprise 40
  BD recorded $75 million of charges for various legal matters during the first nine months of fiscal 2026, up from $64 million in the prior-year period, an increase exceeding 10%. The legal charges were included in the…
• Operating Margin DriversImportance 35 · Surprise 22
  Third-quarter cost of products sold increased 7.1% to $2.668 billion from $2.491 billion, faster than the 5.4% revenue increase. Selling and administrative expense rose 8.4% to $1.261 billion, while research and…
• Revenue Performance and MixImportance 31 · Surprise 32
  Third-quarter fiscal 2026 revenue increased 5.4% as reported and 4.4% on a foreign-currency-neutral basis to $4.983 billion from $4.726 billion. United States revenue rose 6.9% to $3.081 billion, while international…
• Products and TechnologyImportance 31 · Surprise 42
  BD launched the Elyra™ Thulium Fiber Laser System, expanding its kidney stone care portfolio for urology teams. The company also highlighted the BD® CentroVena One™ Insertion System, designed to simplify central line…
• Customer DynamicsImportance 31 · Surprise 42
  BD was awarded a Vizient Innovative Technology contract for the BD® CentroVena One™ Insertion System. The award validates the system as a breakthrough innovation for central line insertion and patient and clinician…

News · 2026-08-06

• Acquisitions and DivestituresImportance 71 · Surprise 60
  BD completed the spin-off of its former Biosciences and Diagnostic Solutions business and its combination with Waters Corporation. The transaction generated a $4 billion cash distribution to BD, which the company used…
• Free Cash Flow and LiquidityImportance 70 · Surprise 56
  Year-to-date cash flow from continuing operations increased 33.3% to $2.1 billion in fiscal 2026. Year-to-date free cash flow increased 44.6% to $1.7 billion. The improvement strengthens liquidity available for debt…
• Capital Return ProgramImportance 64 · Surprise 42
  BD received a $4 billion cash distribution following the separation and combination of its former Biosciences and Diagnostic Solutions business with Waters Corporation. The company allocated the proceeds between share…
• Guidance / OutlookImportance 51 · Surprise 60
  BD raised its fiscal 2026 adjusted diluted EPS guidance midpoint to $12.67 and expects revenue growth toward the high end of its previously stated range. Third-party reporting attributed the improved outlook to…
• Revenue Performance and MixImportance 43 · Surprise 32
  Third-quarter fiscal 2026 revenue was $4.983 billion, up 5.4% as reported and 4.4% on an FX-neutral basis year over year. Growth was broad-based across BD Medical Essentials, Connected Care, BioPharma Systems, and…
• Regulatory RiskImportance 37 · Surprise 42
  BD continues to address unresolved FDA Warning Letters concerning its El Paso manufacturing facility and its Dispensing quality management system. The reported regulatory matters could affect operations and create…
• Operating Income and MarginsImportance 31 · Surprise 32
  Third-quarter adjusted operating margin was 24.9%, down 130 basis points from the prior-year period. Margin pressure reflected tariffs and ongoing investments despite broad-based revenue growth. The company cited…

News · 2026-08-05

• Licensing / Collaboration DealsImportance 31 · Surprise 42
  BD partnered with EMS to launch a semaglutide therapy in Brazil using BD’s Vystra injection pen. The initiative expands BD’s drug-delivery-device presence in Brazil and links its pen technology to the country’s GLP-1…